Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026)
Genmab A (GMAB) posted Total Non-Current Liabilities of $5.5 billion for Q1 2026, down 1.48% on a QoQ basis from $5.6 billion in Q4 2025, and up 932.96% year-over-year from $534.0 million in Q1 2025.
Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Genmab A's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $5.5 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 932.96% year-over-year to $5.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 billion (up 932.96% YoY) and the FY2025 annual result came in at $5.6 billion, up 950.47% from the prior year.
- Total Non-Current Liabilities was $5.5 billion for Q1 2026 at Genmab A, down from $5.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.6 billion in Q4 2025 and bottomed at $177.0 million in Q4 2023.
- A 4-year average of $1.9 billion and a median of $533.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 201.13% — and 2025, when it soared 950.47%.
- Genmab A's Total Non-Current Liabilities stood at $177.0 million in 2023, then surged by 201.13% to $533.0 million in 2024, then surged by 950.47% to $5.6 billion in 2025, then fell by 1.48% to $5.5 billion in 2026.
- Business Quant data shows GMAB's Total Non-Current Liabilities at $5.5 billion in Q1 2026, $5.6 billion in Q4 2025, and $529.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 5.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.52 Bn |
| Dec 31, 2025 | 5.60 Bn |
| Sep 30, 2025 | 529.00 Mn |
| Jun 30, 2025 | 533.00 Mn |
| Mar 31, 2025 | 534.00 Mn |
| Dec 31, 2024 | 533.00 Mn |
| Dec 31, 2023 | 177.00 Mn |
| Sep 30, 2020 | 787.00 |
| Dec 31, 2019 | 158.00 |
| Sep 30, 2019 | 160.91 Mn |